MX2020007495A - Formulacion de adenovirus del grupo b. - Google Patents
Formulacion de adenovirus del grupo b.Info
- Publication number
- MX2020007495A MX2020007495A MX2020007495A MX2020007495A MX2020007495A MX 2020007495 A MX2020007495 A MX 2020007495A MX 2020007495 A MX2020007495 A MX 2020007495A MX 2020007495 A MX2020007495 A MX 2020007495A MX 2020007495 A MX2020007495 A MX 2020007495A
- Authority
- MX
- Mexico
- Prior art keywords
- adenovirus
- group
- containing formulation
- glycerol
- ethanol
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente descripción proporciona una formulación líquida adecuada para un adenovirus del grupo B, que comprende: a) un adenovirus del grupo B, tal como el adenovirus del grupo B competente para replicación, b) 15 a 25 % v/v de glicerol, por ejemplo 16, 17, 18, 19, 20, 21 % v/v de glicerol; y c) 0.1 a 1.5 % v/v de etanol, por ejemplo 0.2-1 %, tal como 1 % v/v de etanol; y d) un tampón, y e) opcionalmente un aminoácido, en donde el pH de la formulación está en el intervalo de 8.0 a 9.6, y uso del mismo en el tratamiento, en particular en el tratamiento del cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1801614.7A GB201801614D0 (en) | 2018-01-31 | 2018-01-31 | Formulation |
| PCT/EP2019/052398 WO2019149829A1 (en) | 2018-01-31 | 2019-01-31 | Group b adenovirus-containing formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007495A true MX2020007495A (es) | 2020-11-12 |
Family
ID=61558316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007495A MX2020007495A (es) | 2018-01-31 | 2019-01-31 | Formulacion de adenovirus del grupo b. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11998580B2 (es) |
| EP (1) | EP3746128A1 (es) |
| JP (2) | JP7491843B2 (es) |
| KR (1) | KR102794512B1 (es) |
| CN (1) | CN111727062A (es) |
| AU (1) | AU2019214397A1 (es) |
| BR (1) | BR112020014248A2 (es) |
| CA (1) | CA3088350A1 (es) |
| CL (1) | CL2020001821A1 (es) |
| CO (1) | CO2020009524A2 (es) |
| EA (1) | EA202091318A1 (es) |
| GB (1) | GB201801614D0 (es) |
| IL (1) | IL276011B (es) |
| MX (1) | MX2020007495A (es) |
| PH (1) | PH12020551057A1 (es) |
| SG (1) | SG11202005746RA (es) |
| WO (1) | WO2019149829A1 (es) |
| ZA (1) | ZA202003615B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014338864C1 (en) | 2013-10-25 | 2020-07-16 | Akamis Bio Limited | Oncolytic adenoviruses armed with heterologous genes |
| PE20180241A1 (es) | 2015-04-30 | 2018-01-31 | Psioxus Therapeutics Ltd | Adenovirus oncolitico que codifica una proteina b7 |
| EA201891022A1 (ru) | 2015-12-17 | 2019-01-31 | Псайоксус Терапьютикс Лимитед | Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| WO2022040319A2 (en) * | 2020-08-18 | 2022-02-24 | New York Genome Center, Inc. | Methods and compositions for inhibiting viral infection |
| GB202102049D0 (en) | 2021-02-13 | 2021-03-31 | Psioxus Therapeutics Ltd | Viruses |
| CN114601838B (zh) * | 2022-04-29 | 2023-10-27 | 广东龙帆生物科技有限公司 | 一种azd8055在制备用于抗腺病毒感染的药物中的用途 |
| CN117618549A (zh) * | 2022-08-09 | 2024-03-01 | 康希诺生物股份公司 | 一种基于黑猩猩腺病毒载体疫苗液体制剂及制备方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0170269A3 (en) | 1984-08-02 | 1987-09-23 | Kao Corporation | Medicated cosmetic compositions |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| DE19648650C2 (de) | 1996-01-29 | 1998-07-02 | Schering Ag | Puffersysteme und deren Verwendung zur Stabilisierung pharmazeutischer Zubereitung |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| IL135507A0 (en) | 1997-10-09 | 2001-05-20 | Pro Virus Inc | Treatment of neoplasms with viruses |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| EP1155120B1 (fr) | 1999-02-22 | 2006-07-05 | Transgene S.A. | Procede d'obtention d'une preparation virale purifiee |
| CZ20013560A3 (cs) | 1999-04-09 | 2002-01-16 | Aventis Pharma S. A. | Tekutý nebo zmrazený přípravek určený k uchování rekombinantních infekčních adenovirů |
| PT1916258E (pt) | 1999-08-09 | 2014-07-29 | Genzyme Corp | Aumento da expressão de uma sequência nucleotídica heteróloga de cadeia simples a partir de vectores virais recombinantes por concepção da sequência de maneira que esta forme pares de bases intracadeia |
| US7456009B2 (en) * | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| DE602004030811D1 (de) | 2003-10-16 | 2011-02-10 | Micromet Ag | Multispezifische deimmunisierte cd3-bindende moleküle |
| US7510868B2 (en) | 2004-05-26 | 2009-03-31 | Paul Harden | Chimeric adenoviruses for use in cancer treatment |
| US20060205080A1 (en) * | 2005-03-01 | 2006-09-14 | David Frey | Formulations for therapeutic viruses having enhanced storage stability |
| CN1961961B (zh) * | 2005-11-11 | 2010-05-26 | 深圳市源兴生物医药科技有限公司 | 一种药物制剂及其制备方法 |
| US20110034560A1 (en) | 2008-01-29 | 2011-02-10 | Sven Jacobson | Liquid formulations of compounds active at sulfonylurea receptors |
| CN101381742A (zh) | 2008-10-23 | 2009-03-11 | 浙江理工大学 | 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用 |
| US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| MY169358A (en) | 2011-08-23 | 2019-03-26 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| AU2012328524B2 (en) * | 2011-10-28 | 2017-05-18 | Excelse Bio, Inc. | Protein formulations containing amino acids |
| AU2013255511B2 (en) | 2012-05-04 | 2016-01-28 | Pfizer Inc. | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
| RU2671558C2 (ru) * | 2013-06-14 | 2018-11-02 | Псайоксус Терапьютикс Лимитед | Режим введения и составы для аденовирусов типа в |
| WO2015040234A1 (en) | 2013-09-23 | 2015-03-26 | Crucell Holland B.V. | Adenovirus formulations |
| GB201318793D0 (en) | 2013-10-24 | 2013-12-11 | Plaquetec Ltd | Vascular Biomarkers |
| AU2014338864C1 (en) | 2013-10-25 | 2020-07-16 | Akamis Bio Limited | Oncolytic adenoviruses armed with heterologous genes |
| IL292311A (en) | 2014-04-03 | 2022-06-01 | Igm Biosciences Inc | J-chain qualified |
| US20170313990A1 (en) | 2014-08-27 | 2017-11-02 | Psioxus Therapeutics Limited | A process for the production of adenovirus |
| PE20180241A1 (es) | 2015-04-30 | 2018-01-31 | Psioxus Therapeutics Ltd | Adenovirus oncolitico que codifica una proteina b7 |
| US20210198689A1 (en) | 2016-03-18 | 2021-07-01 | Nant Holdings Ip, Llc | Multimodal Vector for Dendritic Cell Infection |
| CA3040296A1 (en) | 2016-10-20 | 2018-04-26 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
-
2018
- 2018-01-31 GB GBGB1801614.7A patent/GB201801614D0/en not_active Ceased
-
2019
- 2019-01-31 CA CA3088350A patent/CA3088350A1/en active Pending
- 2019-01-31 AU AU2019214397A patent/AU2019214397A1/en not_active Abandoned
- 2019-01-31 US US16/965,549 patent/US11998580B2/en active Active
- 2019-01-31 CN CN201980008189.XA patent/CN111727062A/zh active Pending
- 2019-01-31 SG SG11202005746RA patent/SG11202005746RA/en unknown
- 2019-01-31 BR BR112020014248-4A patent/BR112020014248A2/pt not_active IP Right Cessation
- 2019-01-31 KR KR1020207022489A patent/KR102794512B1/ko active Active
- 2019-01-31 IL IL276011A patent/IL276011B/en unknown
- 2019-01-31 MX MX2020007495A patent/MX2020007495A/es unknown
- 2019-01-31 WO PCT/EP2019/052398 patent/WO2019149829A1/en not_active Ceased
- 2019-01-31 JP JP2020538999A patent/JP7491843B2/ja active Active
- 2019-01-31 EP EP19706388.6A patent/EP3746128A1/en active Pending
- 2019-01-31 EA EA202091318A patent/EA202091318A1/ru unknown
-
2020
- 2020-06-17 ZA ZA2020/03615A patent/ZA202003615B/en unknown
- 2020-07-08 CL CL2020001821A patent/CL2020001821A1/es unknown
- 2020-07-09 PH PH12020551057A patent/PH12020551057A1/en unknown
- 2020-07-30 CO CONC2020/0009524A patent/CO2020009524A2/es unknown
-
2024
- 2024-01-22 JP JP2024007320A patent/JP2024045278A/ja active Pending
- 2024-04-18 US US18/639,598 patent/US20240398879A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240398879A1 (en) | 2024-12-05 |
| CN111727062A (zh) | 2020-09-29 |
| GB201801614D0 (en) | 2018-03-14 |
| IL276011B (en) | 2022-08-01 |
| IL276011A (en) | 2020-08-31 |
| AU2019214397A1 (en) | 2020-08-13 |
| JP2024045278A (ja) | 2024-04-02 |
| PH12020551057A1 (en) | 2021-08-23 |
| KR20200115525A (ko) | 2020-10-07 |
| SG11202005746RA (en) | 2020-08-28 |
| KR102794512B1 (ko) | 2025-04-11 |
| WO2019149829A1 (en) | 2019-08-08 |
| JP7491843B2 (ja) | 2024-05-28 |
| EP3746128A1 (en) | 2020-12-09 |
| CA3088350A1 (en) | 2019-08-08 |
| US11998580B2 (en) | 2024-06-04 |
| EA202091318A1 (ru) | 2020-11-13 |
| ZA202003615B (en) | 2021-09-29 |
| CO2020009524A2 (es) | 2020-08-21 |
| US20210121512A1 (en) | 2021-04-29 |
| BR112020014248A2 (pt) | 2020-12-15 |
| JP2021512054A (ja) | 2021-05-13 |
| CL2020001821A1 (es) | 2020-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020007495A (es) | Formulacion de adenovirus del grupo b. | |
| UY38221A (es) | Inhibidores de proteínas ras con g12c mutantes | |
| WO2019222112A8 (en) | Mcl-1 inhibitors | |
| WO2019191229A8 (en) | Compounds for treating huntington's disease | |
| WO2021021837A3 (en) | Anti-pvrig antibodies formulations and uses thereof | |
| WO2019147749A3 (en) | Stabilized rsv f proteins and uses thereof | |
| MX389718B (es) | Formulaciones y metodos de tratamiento con queratina. | |
| BR112022004972A2 (pt) | Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso | |
| BR112022008558A2 (pt) | Método de tratamento para câncer, tratamento de combinação de nivolumabe e anticorpos anti-pvrig, e, uso | |
| UY36542A (es) | Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa | |
| PH12021552521A1 (en) | Aqueous pharmaceutical composition of an anti-il17a antibody and use thereof | |
| WO2018094023A3 (en) | Cyclic dipeptides and wound healing | |
| NZ702342A (en) | Pharmaceutical formulation | |
| EP4477265A3 (en) | Methods of treating new-onset plaque type psoriasis using il-17 antagonists | |
| PH12021551475A1 (en) | Heterodimeric proteins for modulating gamma delta t cells | |
| AU2018282105A1 (en) | Dosing of vibegron for treatment of overactive bladder | |
| WO2017098051A3 (en) | Combined preparations of pkm2 modulators and hmgb1 | |
| WO2020254663A3 (en) | Compositions and methods using thymol and/or carvacrol for induction of autophagy | |
| MX2024012565A (es) | Composiciones farmaceuticas de mosunetuzumab y metodos de uso | |
| ECSP24028472A (es) | Administración facilitada de formulaciones concentradas de anticuerpos mediante el uso de hialuronidasa | |
| TR201904382T4 (tr) | Vajinit tedavisi. | |
| MX2021005015A (es) | Formulaciones farmaceuticas acuosas. | |
| MX2021008812A (es) | Composicion cosmetica/dermatologica. | |
| WO2015166355A3 (en) | Targeted therapy to restore radioactive iodine transport in thyroid cancer | |
| WO2019100079A8 (en) | Compositions for improving car-t cell functionality and use thereof |